{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T18:04:12Z","timestamp":1783533852469,"version":"3.55.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2016,7,22]],"date-time":"2016-07-22T00:00:00Z","timestamp":1469145600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Taiwan Department of Health grant","award":["DOH101-TD-B-111-01"],"award-info":[{"award-number":["DOH101-TD-B-111-01"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1007\/s00228-016-2097-y","type":"journal-article","created":{"date-parts":[[2016,7,22]],"date-time":"2016-07-22T01:31:12Z","timestamp":1469151072000},"page":"1265-1273","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Use of cardioselective \u03b2-blockers and overall death and cardiovascular outcomes in patients with COPD: a population-based cohort study"],"prefix":"10.1007","volume":"72","author":[{"given":"Yaa-Hui","family":"Dong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Hsuin","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Chiu","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei-Shu","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,7,22]]},"reference":[{"key":"2097_CR1","unstructured":"Global Initiative for Chronic Obstructive Lung Disease, Global strategy for the Diagnosis, management and prevention of chronic obstructive pulmonary diseases (2013) http:\/\/www.goldcopd.org\/uploads\/users\/files\/GOLD_Report_2013_Feb20.pdf . Accessed July 5, 2014"},{"key":"2097_CR2","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1513\/pats.200404-032MS","volume":"2","author":"DD Sin","year":"2005","unstructured":"Sin DD, Man SFP (2005) Chronic obstructive pulmonary disease as a risk factor for cardiovascular morbidity and mortality. Proc Am Thorac Soc 2:8\u201311","journal-title":"Proc Am Thorac Soc"},{"key":"2097_CR3","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.annepidem.2005.04.008","volume":"16","author":"SM Curkendall","year":"2006","unstructured":"Curkendall SM, DeLuise C, Jones JK, et al. (2006) Cardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan Canada cardiovascular disease in COPD patients. Ann Epidemiol 16:63\u201370","journal-title":"Ann Epidemiol"},{"key":"2097_CR4","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1378\/chest.128.4.2640","volume":"128","author":"L Huiart","year":"2005","unstructured":"Huiart L, Ernst P, Suissa S (2005) Cardiovascular morbidity and mortality in COPD. Chest 128:2640\u20132646","journal-title":"Chest"},{"key":"2097_CR5","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1001\/jama.1994.03520190043033","volume":"272","author":"NR Anthonisen","year":"1994","unstructured":"Anthonisen NR, Connett JE, Kiley JP, et al. (1994) Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA 272:1497\u20131505","journal-title":"JAMA"},{"key":"2097_CR6","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1016\/j.jacc.2011.10.824","volume":"58","author":"SC Smith Jr","year":"2011","unstructured":"Smith SC Jr, Benjamin EJ, Bonow RO, et al. (2011) AHA\/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation endorsed by the World Heart Federation and the Preventive Cardiovascular Nurses Association. J Am Coll Cardiol 58:2432\u20132446","journal-title":"J Am Coll Cardiol"},{"key":"2097_CR7","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1136\/bmj.318.7200.1730","volume":"318","author":"N Freemantle","year":"1999","unstructured":"Freemantle N, Cleland J, Young P, Mason J, Harrison J (1999) Beta blockade after myocardial infarction: systematic review and meta regression analysis. BMJ 318:1730\u20131737","journal-title":"BMJ"},{"key":"2097_CR8","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1056\/NEJM199808203390801","volume":"339","author":"SS Gottlieb","year":"1998","unstructured":"Gottlieb SS, McCarter RJ, Vogel RA (1998) Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med 339:489\u2013497","journal-title":"N Engl J Med"},{"key":"2097_CR9","doi-asserted-by":"crossref","first-page":"f6650","DOI":"10.1136\/bmj.f6650","volume":"347","author":"JK Quint","year":"2013","unstructured":"Quint JK, Herrett E, Bhaskaran K, et al. (2013) Effect of \u03b2 blockers on mortality after myocardial infarction in adults with COPD: population based cohort study of UK electronic healthcare records. BMJ 347:f6650","journal-title":"BMJ"},{"key":"2097_CR10","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1016\/S0735-1097(01)01225-6","volume":"37","author":"J Chen","year":"2001","unstructured":"Chen J, Radford MJ, Wang Y, Marciniak TA, Krumholz HM (2001) Effectiveness of beta-blocker therapy after acute myocardial infarction in elderly patients with chronic obstructive pulmonary disease or asthma. J Am Coll Cardiol 37:1950\u20131956","journal-title":"J Am Coll Cardiol"},{"key":"2097_CR11","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.athoracsur.2012.07.080","volume":"95","author":"E Angeloni","year":"2013","unstructured":"Angeloni E, Melina G, Roscitano A, et al. (2013) \u03b2-Blockers improve survival of patients with chronic obstructive pulmonary disease after coronary artery bypass grafting. Ann Thorac Surg 95:525\u2013531","journal-title":"Ann Thorac Surg"},{"key":"2097_CR12","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1164\/rccm.200803-384OC","volume":"178","author":"YR Gestel van","year":"2008","unstructured":"van Gestel YR, Hoeks SE, Sin DD, et al. (2008) Impact of cardioselective beta-blockers on mortality in patients with chronic obstructive pulmonary disease and atherosclerosis. Am J Respir Crit Care Med 178:695\u2013700","journal-title":"Am J Respir Crit Care Med"},{"key":"2097_CR13","doi-asserted-by":"crossref","first-page":"d2549","DOI":"10.1136\/bmj.d2549","volume":"342","author":"PM Short","year":"2011","unstructured":"Short PM, Lipworth SI, Elder DH, Schembri S, Lipworth BJ (2011) Effect of beta blockers in treatment of chronic obstructive pulmonary disease: a retrospective cohort study. BMJ 342:d2549","journal-title":"BMJ"},{"key":"2097_CR14","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1001\/archinternmed.2010.112","volume":"170","author":"FH Rutten","year":"2010","unstructured":"Rutten FH, Zuithoff NP, Hak E, Grobbee DE, Hoes AW (2010) Beta-blockers may reduce mortality and risk of exacerbations in patients with chronic obstructive pulmonary disease. Arch Intern Med 170:880\u2013887","journal-title":"Arch Intern Med"},{"key":"2097_CR15","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.amjmed.2004.07.043","volume":"117","author":"A DH","year":"2004","unstructured":"DH A, Bryson CL, Fan VS, et al. (2004) Beta-blockers as single-agent therapy for hypertension and the risk of mortality among patients with chronic obstructive pulmonary disease. Am J Med 117:925\u2013931","journal-title":"Am J Med"},{"issue":"Suppl 3","key":"2097_CR16","first-page":"S45","volume":"52","author":"DS Lee","year":"2014","unstructured":"Lee DS, Markwardt S, McAvay GJ, et al. (2014) Effect of \u03b2-blockers on cardiac and pulmonary events and death in older adults with cardiovascular disease and chronic obstructive pulmonary disease. Med Care 52(Suppl 3):S45\u2013S51","journal-title":"Med Care"},{"key":"2097_CR17","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1164\/rccm.201208-1565OC","volume":"187","author":"MP Ekstr\u00f6m","year":"2013","unstructured":"Ekstr\u00f6m MP, Hermansson AB, Str\u00f6m KE (2013) Effects of cardiovascular drugs on mortality in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 187:715\u2013720","journal-title":"Am J Respir Crit Care Med"},{"key":"2097_CR18","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/pds.1200","volume":"15","author":"S Schneeweiss","year":"2006","unstructured":"Schneeweiss S (2006) Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics. Pharmacoepidemiol Drug Saf 15:291\u2013303","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2097_CR19","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1136\/ip.8.4.276","volume":"8","author":"WA Ray","year":"2002","unstructured":"Ray WA, Daugherty JR, Griffin MR (2002) Lipid-lowering agents and the risk of hip fracture in a Medicaid population. Inj Prev 8:276\u2013279","journal-title":"Inj Prev"},{"key":"2097_CR20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/pds.3334","volume":"22","author":"ES Johnson","year":"2013","unstructured":"Johnson ES, Bartman BA, Briesacher BA, et al. (2013) The incident user design in comparative effectiveness research. Pharmacoepidemiol Drug Saf 22:1\u20136","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2097_CR21","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1093\/aje\/kwr301","volume":"175","author":"G Danaei","year":"2012","unstructured":"Danaei G, Tavakkoli M, Hern\u00e1n MA (2012) Bias in observational studies of prevalent users: lessons for comparative effectiveness research from a meta-analysis of statins. Am J Epidemiol 175:250\u2013262","journal-title":"Am J Epidemiol"},{"key":"2097_CR22","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1378\/chest.127.3.818","volume":"127","author":"HJ Woude van der","year":"2005","unstructured":"van der Woude HJ, Zaagsma J, Postma DS, Winter TH, van Hulst M, Aalbers R (2005) Detrimental effects of beta-blockers in COPD: a concern for nonselective beta-blockers. Chest 127:818\u2013824","journal-title":"Chest"},{"key":"2097_CR23","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.amjcard.2008.09.081","volume":"103","author":"BA Olenchock","year":"2009","unstructured":"Olenchock BA, Fonarow GG, Pan W, et al. (2009) Current use of beta blockers in patients with reactive airway disease who are hospitalized with acute coronary syndromes. Am J Cardiol 103:295\u2013300","journal-title":"Am J Cardiol"},{"key":"2097_CR24","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1093\/qjmed\/hci080","volume":"98","author":"M Egred","year":"2005","unstructured":"Egred M, Shaw S, Mohammad B, Waitt P, Rodrigues E (2005) Under-use of beta-blockers in patients with ischaemic heart disease and concomitant chronic obstructive pulmonary disease. QJM 98:493\u2013497","journal-title":"QJM"},{"key":"2097_CR25","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1378\/chest.128.5.3618","volume":"128","author":"S Andreas","year":"2005","unstructured":"Andreas S, Anker SD, Scanlon PD, Somers VK (2005) Neurohumoral activation as a link to systemic manifestations of chronic lung disease. Chest 128:3618\u20133624","journal-title":"Chest"},{"key":"2097_CR26","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.jacc.2007.04.079","volume":"50","author":"K Fox","year":"2007","unstructured":"Fox K, Borer JS, Camm AJ, et al. (2007) Resting heart rate in cardiovascular disease. J Am Coll Cardiol 50:823\u2013830","journal-title":"J Am Coll Cardiol"},{"key":"2097_CR27","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1592\/phco.29.9.1039","volume":"29","author":"TA Lee","year":"2009","unstructured":"Lee TA, Schumock GT, Bartle B, Pickard AS (2009) Mortality risk in patients receiving drug regimens with theophylline for chronic obstructive pulmonary disease. Pharmacotherapy 29:1039\u20131053","journal-title":"Pharmacotherapy"},{"key":"2097_CR28","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1002\/pds.3921","volume":"25","author":"JS Floyd","year":"2016","unstructured":"Floyd JS, Blondon M, Moore KP, Boyko EJ, Smith NL (2016) Validation of methods for assessing cardiovascular disease using electronic health data in a cohort of veterans with diabetes. Pharmacoepidemiol Drug Saf 25:467\u2013471","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2097_CR29","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1097\/01.mlr.0000160417.39497.a9","volume":"43","author":"E Birman-Deych","year":"2005","unstructured":"Birman-Deych E, Waterman AD, Yan Y, Nilasena DS, Radford MJ, Gage BF (2005) Accuracy of ICD-9-CM codes for identifying cardiovascular and stroke risk factors. Med Care 43:480\u2013485","journal-title":"Med Care"},{"key":"2097_CR30","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1136\/bmj.330.7497.960","volume":"330","author":"M Mamadani","year":"2005","unstructured":"Mamadani M, Sykora K, Li P, et al. (2005) Readers\u2019 guide to critical appraisal of cohort studies: 2. Assessing potential for confounding. BMJ 330:960\u2013962","journal-title":"BMJ"},{"key":"2097_CR31","doi-asserted-by":"crossref","first-page":"948","DOI":"10.2307\/2533848","volume":"54","author":"DY Lin","year":"1998","unstructured":"Lin DY, Psaty BM, Kronmal RA (1998) Assessing the sensitivity of regression results to unmeasured confounders in observational studies. Biometrics 54:948\u2013963","journal-title":"Biometrics"},{"key":"2097_CR32","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1164\/rccm.201207-1299OC","volume":"186","author":"P Lange","year":"2012","unstructured":"Lange P, Marott JL, Vestbo J, Olsen KR, Ingebrigtsen TS, Dahl M, Nordestgaard BG (2012) Prediction of the clinical course of chronic obstructive pulmonary disease, using the new GOLD classification: a study of the general population. Am J Respir Crit Care Med 186:975\u2013981","journal-title":"Am J Respir Crit Care Med"},{"key":"2097_CR33","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.pupt.2007.06.003","volume":"21","author":"R Lin","year":"2008","unstructured":"Lin R, Peng H, Nguyen LP, et al. (2008) Changes in beta 2-adrenoceptor and other signaling proteins produced by chronic administration of \u2018beta-blockers\u2019 in a murine asthma model. Pulm Pharmacol Ther 21:115\u2013124","journal-title":"Pulm Pharmacol Ther"},{"key":"2097_CR34","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1186\/cc8026","volume":"13","author":"E Montmollin de","year":"2009","unstructured":"de Montmollin E, Aboab J, Mansart A, Annane D (2009) Bench-to-bedside review: beta-adrenergic modulation in sepsis. Crit Care 13:230","journal-title":"Crit Care"},{"key":"2097_CR35","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.ahj.2008.02.023","volume":"156","author":"S Bangalore","year":"2008","unstructured":"Bangalore S, Messerli FH, Cohen JD, et al. (2008) Verapamil-sustained release-based treatment strategy is equivalent to atenolol-based treatment strategy at reducing cardiovascular events in patients with prior myocardial infarction: an INternational VErapamil SR-Trandolapril (INVEST) substudy. Am Heart J 156:241\u2013247","journal-title":"Am Heart J"},{"key":"2097_CR36","doi-asserted-by":"crossref","first-page":"e83725","DOI":"10.1371\/journal.pone.0083725","volume":"8","author":"Y Shibata","year":"2013","unstructured":"Shibata Y, Inoue S, Igarashi A, et al. (2013) A lower level of forced expiratory volume in 1\u00a0second is a risk factor for all-cause and cardiovascular mortality in a Japanese population: the Takahata study. PLoS One 8:e83725","journal-title":"PLoS One"},{"key":"2097_CR37","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s10654-006-9066-1","volume":"21","author":"SM Curkendall","year":"2006","unstructured":"Curkendall SM, Lanes S, de Luise C, Stang MR, Jones JK, She D, Goehring E Jr (2006) Chronic obstructive pulmonary disease severity and cardiovascular outcomes. Eur J Epidemiol 21:803\u2013813","journal-title":"Eur J Epidemiol"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-016-2097-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-016-2097-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-016-2097-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T18:58:00Z","timestamp":1498330680000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-016-2097-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,22]]},"references-count":37,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["2097"],"URL":"https:\/\/doi.org\/10.1007\/s00228-016-2097-y","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,22]]}}}